This article is more than 5 years old. Information may no longer be current.
Sanford Burnham Prebys Medical Discovery Institute appoints assistant professor
Click Here to Manage Email Alerts
Brooke Emerling, PhD, has been appointed assistant professor in the cancer metabolism and signaling networks program at Sanford Burnham Prebys Medical Discovery Institute.
“Dr. Emerling is remarkably accomplished, and her research addresses an unmet need in the treatment of breast cancer,” Kristiina Vuori, MD, PhD, president of the institute, said in a press release. “Her future work is highly likely to impact the clinic.”
Emerling previously served as instructor of cancer biology in medicine at Weill Cornell Medicine. She completed a postdoctoral fellowship at Harvard Medical School in 2013.
She has identified a promising new therapeutic target for triple-negative breast cancer and other malignancies driven by the loss of the tumor suppressor p53.
“Unlike the other three major subtypes of breast cancer, triple-negative breast cancer ... is treatable only with standard chemotherapy, which doesn’t always work,” Emerling said in the release. “The lack of specific treatments means that it has a mortality rate three times higher than the other subtypes.”
Emerling said she is excited to join the institute.
“My research fits really well with the interests of several ... faculty, who are doing amazing work in metabolism and autophagy,” she said. “Combined with the collegial, collaborative environment and how great the people are from the top down — it’s exactly where I want to be.”